Century Therapeutics to Participate in Upcoming Investor Conferences in March

Century Therapeutics, Inc. (NASDAQ: IPSC), a pioneering biotechnology company focused on the development of induced pluripotent stem cell (iPSC)-derived therapies, is set to participate in two prominent investor conferences in March 2026. The company specializes in creating innovative cell therapies aimed at treating autoimmune diseases, such as type 1 diabetes, and various forms of cancer.

Scheduled for March 4, 2026, Century will be featured in a fireside chat at the TD Cowen 46th Annual Health Care Conference in Boston, MA, at 9:50 a.m. ET. Following that, on March 10, 2026, the company will participate in another fireside chat at the Leerink Partners Global Healthcare Conference in Miami, FL, commencing at 4:20 p.m. ET. Both sessions promise to provide insights into Century's ongoing advancements and strategic direction.

Investors and interested parties can access live webcasts of these presentations via the Investors page of Century's official website, www.centurytx.com. Additionally, archived recordings will be available for at least 30 days, facilitating broader access to the discussions.

Century Therapeutics is leveraging its unique Allo-Evasion™ technology, which enables the development of off-the-shelf cell therapies designed to enhance patient accessibility and offer significant benefits over traditional treatments. With an emphasis on cutting-edge research and innovation, Century aims to transform the therapeutic landscape for autoimmune diseases and cancers, demonstrating its commitment to expanding treatment options and improving patient care.

For additional information about Century Therapeutics and its revolutionary initiatives in cellular therapies, stakeholders are encouraged to visit their website or connect through LinkedIn. For direct inquiries, investors can reach out to Douglas Carr, Senior Vice President of Finance, at investor.relations@centurytx.com.

Century Therapeutics, Inc. (NASDAQ: IPSC) is poised to attract significant attention during the upcoming investor conferences in March, including the TD Cowen 46th Annual Health Care Conference and the Leerink Partners Global Healthcare Conference. As a biotechnology firm at the forefront of developing induced pluripotent stem cell (iPSC)-derived therapies for autoimmune diseases such as type 1 diabetes and various cancers, Century’s innovations come at a crucial time when the demand for advanced, patient-centric therapies is high.

Investors should monitor Century’s presentations closely, particularly the insightful discussions surrounding its proprietary Allo-Evasion™ technology. This immune evasion engineering approach aims to create off-the-shelf cell therapies that can expand patient access, potentially setting a new standard in the treatment landscape of autoimmune diseases and tumors. Century's focus on iPSC technology enhances its value proposition, as it seeks to address the limitations of current cell therapies, providing a compelling reason for investors to increase their stakes.

Given the dynamic nature of the biotech sector in 2026, and the growing interest in personalized medicine, Century Therapeutics stands out by targeting unmet medical needs with scalable solutions. Investors should consider potential market reactions based on the outcomes of these conferences, especially if the company announces new partnerships, clinical trial updates, or regulatory progress.

In light of the current stock market trends and biotechnology sector performance, investing in Century may align well with a portfolio focused on high-growth opportunities in the healthcare space. However, due diligence is crucial; investors should assess the company's financials, competitive landscape, and regulatory pathway before making investment decisions. Watch for stock price movements following the conferences, which could represent a buying opportunity if the company’s presentations resonate positively with the market.